Background: Breast cancer is the most common cancer of Bangladeshi women. Almost all present with palpable lump and 40% of them are with locally advanced breast cancer. Neoadjuvant chemotherapy is the standard choice of treatment for the patients.
Introduction
Breast cancer is the number one cancer of Bangladeshi women comprising of 24% of all female cancer 1 . Forty percent of them present with locally advanced breast cancer (LABC) 2 • According to the cancer incidence statistics of Bangladesh 14,836 cases are diagnosed as breast cancer every year.3
Among the breast cancer, LABC constitutes a major clinical challenge, because the vast majority of patients with LABC experience disease relapse and eventually die, despite aggressive multimodality treatment. 4 Locally advanced breast cancer (LABC) refers to large breast tumors (> 5 cm) associated with either skin or chest wall involvement or with fixed axillary lymph nodes or with involvement of the ipsilateral internal mammary or supraclavicular nodes. 5 In the TNM staging classification, LABC is represented by stage IIIA (TON2, T1N2, T2N2, T3N1, T3N2), stage IIIB (T4NO, T4N1, T4N2) and stage IIIC disease (any T, N3).
Historically, patients with LABC were treated with radical surgery and/or radiation therapy (RT). However the management of LABC was dramatically transformed over the past two decades 6 • Primary chemotherapy (CT) became an integral part of the multidisciplinary management of LABC, probably prolonging the disease-free survival (DFS) and overall survival (OS), and making breast conserving surgery a possibility for these patients 7. This study observes the clinicopathological response pattern to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
Materials and Methods
This study was conducted in National Institute of Cancer Research & Hospital (NICRH), Mohakhali, Dhaka from January 2010 to December 2014. A total of two hundred forty five patients with locally advanced breast cancer (Stage IIIA, IIIB, and IIIC) were initially enrolled as study population. The patients were treated with four cycle of neoadjuvant chemotherapy. Twenty five patients were excluded since they were at the stage of metastatic disease at the time of diagnosis or failed to receive four cycle of chemotherapy. Therefore, 220 patients were finally eligible for this study. Patients more than 70 years, patients with distant metastasis, vital functions severely compromised (ASA grade Ill & IV) and patient who were did not receive NACT as per schedule were excluded from the study.
The neoadjuvant chemotherapy schedules were 4 cycles which was repeated 3 weekly. The drugs usually used in our center as neoadjuvant for LABC are 4 cycle AC (Adriamycin, Cyclophosphamide) with 3 weekly interval followed by Surgery, then 4 cycle Paclitaxel as adjuvant therapy. The dosages of Doxorubicin was 60 mg/m 2 1V in day 1 and Cyclophospharnide 600 mg/m21V in day1. Then Paclitaxel 175 mg/m 2 1V (3 h infusion) in day 1 .
Before going to neoadjuvant chemotherapy each patient was evaluated clinically, radiologically; routine blood, biochemical test for liver function, kidney function and cardiac function test by ECG and Echocardiogram. Diagnosis was confirmed by FNAC and Core cut biopsy.
Baseline patient and tumor characteristics were recorded including age, tumor size, nodal stage, tumor grade, estrogen receptor (ER) status, progesterone receptor (PR) status and Her 2 status. Clinical response was assessed after first two cycle of chemotherapy and after completion of four cycles. Surgery was done 3-4 weeks after last cycle of chemotherapy.
Responses were recorded according to Union for International Cancer control (UICC) criteria.
A complete clinical response (cCR): original mass became impalpable.
A partial response (cPR): represented a 50% or greater reduction in bi-dimensional tumor measurements.
Progressive disease (cPD): was recorded if bidimensional measurements increased by 20% or more.
Stable disease (cSD): rest of the tumors belong to this group.
Pathological response was assessed at definitive surgery on completion of neoadjuvant chemotherapy.
A pathological complete response (pCR): there was no evidence of residual tumor on histological examination of the surgical specimen.
Results
The median age of the patients at the time of diagnosis was 36(± 5.9) years (range: 25-70). About 55.91% of the patients (n=123) were living in rural areas while 44.09% (n=97) came from urban areas. 152 (69.09%) patients were pre-menopausal while 68 (30.91%) were post-menopausal. The mean tumor diameter measured clinically before neoadjuvant chemotherapy was 7.9 (±1.3) cm (range 4-18 cm). Axillary nodal status was NO in 11 patients (5%), In concordance with previous studies, we have observed the NACT responders were mostly estrogen receptors positive group. So, it was observed in this study that a higher objective response rate (cCR+ pCR) in patients who are ER-positive as compared with ERnegative patients (p=0.886). But interestingly, the results were not found statistically significant. All the patients who attained pCR are ER-positive. This finding seems to contradict the finding from Danishad et al. who identified that ER negative tumors respond better for chemotherapy 14 . Conclusion: Patients with LABC admitted into our center underwent treatment with NACT have shown excellent response through downgrading the tumor size, axillary lymph nodes and pathological response. So, we may conclude here that the conventional neoadjuvant chemotherapy especially the AC regimen is effective in our perspective.
